Migraine Market to Grow Positively at a Paltry CAGR During the Study Period, DelveInsight | Lundbeck Seattle BioPharmaceutical, Eli Lilly and Company, Amgen, Novartis, Teva Pharmaceuticals, Allergan, Biohaven Pharmaceuticals, Dr. Reddy's Labs, AbbVie, Imp

DelveInsight's "Migraine - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Migraine market share of the individual therapies, current and forecasted Migraine market size from 2020 to 2034 segmented by seven major markets. The report also offers current Migraine therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Migraine market.
Download our report @ https://www.delveinsight.com/report-store/migraine-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key highlights from the migraine market report:
In 2023, the migraine market across the 7MM was valued at approximately USD 10,880 million and is projected to grow throughout the forecast period from 2024 to 2034.
Key migraine companies working in the migraine market are Lundbeck Seattle BioPharmaceutical, Eli Lilly and Company, Amgen, Novartis, Teva Pharmaceuticals, Allergan, Biohaven Pharmaceuticals, Dr. Reddy's Labs, AbbVie, Impel NeuroPharma, Zosano Pharma, Axsome Therapeutics, Aeon Biopharma Inc., Ionis Pharmaceuticals, Inc., Charleston Laboratories, and others.
The US had the largest migraine market size in 2023, totaling around USD 6,790 million, with expectations for continued growth by 2034. The rising prevalence of migraines is attributed to increased awareness, lifestyle changes, environmental factors, genetic predisposition, an aging population, hormonal fluctuations, technological advancements, and psychological stressors. Addressing this issue will require comprehensive strategies spanning healthcare, research, and public policy.
In 2023, the US held the largest share of migraine cases in the 7MM, representing 39% of the total, followed by Japan with about 14%. Among European countries, the UK had the highest number of cases, accounting for roughly 11% of the total 7MM cases.

Migraine Overview
Migraine is a complex neurological disorder that includes various types, such as migraine without aura, migraine with aura, and chronic migraine. Common symptoms are throbbing head pain, nausea, vomiting, and sensitivity to light and sound. The causes of migraine are multifactorial, involving genetic predisposition, environmental triggers, hormonal fluctuations, and neurological dysfunction.

Migraines can be categorized based on attack frequency: episodic migraine occurs less than 15 days per month, while chronic migraine occurs on 15 or more days per month for at least three months. Chronic migraine is particularly burdensome and requires more intensive management. Migraine significantly impacts quality of life, productivity, and mental health.

Diagnosis involves assessing symptoms, reviewing medical history, and excluding other conditions. Challenges in diagnosis include symptom variability, a lack of specific diagnostic tests, and overlap with other disorders, which can lead to underrecognition and misdiagnosis. Additionally, migraines are often underreported due to stigma or normalization of symptoms, which can delay appropriate intervention. Enhancing awareness among healthcare providers and the public, along with developing more precise diagnostic tools, is crucial for better management.

Traditional treatment goals for migraines include pain relief, functional restoration, and reducing headache frequency, with an emphasis on preventing the progression from episodic to chronic migraine. Optimal management also involves addressing comorbidities. Treatment decisions are guided by migraine type (episodic or chronic), severity, previous treatments, and patient preferences. Clinicians must also consider comorbid conditions and potential drug interactions. Treatment strategies encompass education, lifestyle changes, trigger management, and both acute and preventive pharmacotherapy. While prevention may not be necessary for every episodic migraine patient, it is essential for all individuals with chronic migraine.
To know more about migraine, visit: https://www.delveinsight.com/report-store/migraine-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Migraine Epidemiological Insights
In 2023, there were approximately 119,233 prevalent cases of migraine across the 7MM. In the US alone, the number of migraine cases is projected to grow significantly, with an expected CAGR leading to around 46,140 cases by 2034.
Among European countries, Germany had the highest prevalence of migraine at 22%, followed by Italy. Spain had the lowest prevalence, accounting for about 17% in the same year. However, migraine prevalence is anticipated to decline in Germany and Japan due to factors such as population changes.
In Japan, the majority of migraine cases were episodic, with approximately 16,331 cases, while chronic migraine cases were relatively fewer at around 950. DelveInsight's analysis indicates that females represent the majority of migraine cases compared to males, with approximately 11,535 male and 34,605 female cases in the US in 2023.
In the EU4 and the UK, episodic migraine was the most common type, with around 15,839 cases, whereas chronic migraine was less common, with approximately 2,411 cases in 2023.
Migraine Treatment Market
Migraine is a prevalent neurological disorder characterized by throbbing, unilateral headaches often accompanied by light sensitivity (photophobia), sound sensitivity (phonophobia), and nausea. These attacks can severely impact quality of life and are a leading cause of disability globally, ranking as the second highest cause of years lost to disability worldwide in 2019.

Recent advancements in understanding migraine pathophysiology have enhanced the ability to characterize and diagnose this condition. Treatment strategies are broadly categorized into acute (abortive) and preventive measures. Acute treatments aim to relieve pain and stop the progression of an ongoing attack, while preventive treatments are used to avoid or mitigate attacks triggered by known factors, such as exercise or hormonal changes.

In the acute treatment market, key therapeutic classes include triptans, NSAIDs, analgesics/opioids, and dihydroergotamine (DHE) or ergot alkaloids. Triptans remain the leading class due to their effectiveness and favorable side effect profile. Prominent triptans include eletriptan, almotriptan, sumatriptan, rizatriptan, and zolmitriptan. These are generally preferred over DHE due to better tolerability and efficacy. For mild-to-moderate attacks, acetaminophen, aspirin, and NSAIDs are commonly used.

Preventive therapies aim to decrease the frequency, severity, and duration of migraine attacks. FDA-approved preventive agents include propranolol, timolol, divalproex sodium, OnabotulinumtoxinA (Botox), and topiramate. Botox is notable for being a non-daily injectable option with fewer side effects compared to daily oral medications, and it is specifically approved for chronic migraine.

The field is evolving with the identification of key biomarkers such as the serotonin 1F (5-HT1F) receptor and calcitonin gene-related peptide (CGRP), which are promising targets for treatment. A significant development in 2019 was the FDA approval of three CGRP monoclonal antibodies (mAbs) for migraine prevention: Aimovig (erenumab) by Novartis/Amgen, Ajovy (fremanezumab) by Teva, and Emgality (galcanezumab) by Eli Lilly. These represent the first new migraine-specific drugs approved since Botox's expanded use for chronic migraine in 2010.

Promising Therapies in the Migraine Pipeline
INP104
And others
Discover more about Migraine therapies in the pipeline @ https://www.delveinsight.com/sample-request/migraine-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Migraine Market
Impel NeuroPharma
And others
To understand key companies related to the Migraine Market, get a snapshot of the Migraine Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/migraine-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Migraine Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Migraine Companies: Impel NeuroPharma, and others
Key Migraine Pipeline Therapies: INP104, and others
Therapeutic Assessment: Migraine current marketed and emerging therapies
Migraine Market Dynamics: Migraine market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Migraine Market Access and Reimbursement
Table of Contents
1. Migraine Market Key Insights
2. Migraine Market Report Introduction
3. Migraine Market Overview at a Glance
4. Migraine Market Executive Summary
5. Disease Background and Overview
6. Migraine Treatment and Management
7. Migraine Epidemiology and Patient Population
8. Patient Journey
9. Migraine Emerging Drugs
10. 7MM Migraine Market Analysis
11. Migraine Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Migraine Market Drivers
15. Migraine Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.